Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2011

View Archived Issues

Experiments reveal new target and agents to treat autosomal dominant polycystic kidney disease

New PAI-1 inhibitor ameliorates experimental collapsing focal segmental glomerulosclerosis

Effect of hepatic impairment on single-dose pharmacokinetics of daclatasvir investigated

Novel voltage-gated K(V)7 potassium channel modulator has anticonvulsant activity

Cancer therapy Lipotecan advances through first-in-human trial

New arginase inhibitors developed at Mars

Scientists at Roche prepare novel vasopressin V1A receptor antagonists

Pierre Fabre presents new acyl-CoA desaturase inhibitors

U.S. universities synthesize novel HIF-1 inhibitors

Avaxia Biologics raises funds to develop oral antibodies for inflammatory bowel disease

New Rho-associated protein kinase inhibitors patented

Anavex completes phase I trial of ANAVEX 2-73

FDA approves first umbilical cord-derived stem cell product for transplantation

Phase III trial of vorapaxar does not meet primary endpoint

Dyax provides update on European regulatory status of ecallantide

Merck & Co. reports pipeline progress

Eli Lilly and Boehringer Ingelheim begin phase III trials of LY-2605541

Avraham Pharmaceuticals raises funds to advance development of ladostigil

Novartis reports first data from 3-year phase III SMC-021 study

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Shionogi recaps progress made in second quarter of fiscal year 2011

FDA grants priority review to NeurogesX's sNDA for Qutenza

Phase IIa study of Theravance LAMA meets primary endpoint

FDA and EMA accept Astellas' submissions for mirabegron

Gilead Sciences presents highlights of third quarter 2011

Bend Research to provide Merck & Co. with drug delivery technology

Kyowa Hakko Kirin launches new formulation of second-generation antihistamine in Japan